Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P51151
UPID:
RAB9A_HUMAN
Alternative names:
-
Alternative UPACC:
P51151; A8K390; Q6ICN1
Background:
Ras-related protein Rab-9A plays a crucial role in the transport of proteins between the endosomes and the trans Golgi network. It is essential for the recruitment of SGSM2 to melanosomes, facilitating the proper trafficking of melanogenic enzymes TYR, TYRP1, and DCT/TYRP2 in melanocytes.
Therapeutic significance:
Understanding the role of Ras-related protein Rab-9A could open doors to potential therapeutic strategies.